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Background: To investigate the imaging features of primary sarcomas of the great vessels in CT, MRI and 18 F-FDG
PET/CT.
Methods: Thirteen patients with a primary sarcoma of the great vessels were retrospectively evaluated. All available
images studies including F-18 FDG PET(/CT) (n = 4), MDCT (n = 12) and MRI (n = 6) were evaluated and indicative
image features of this rare tumor entity were identified.
Results: The median interval between the first imaging study and the final diagnosis was 11 weeks (0–12 weeks).
The most frequently observed imaging findings suggestive of malignant disease in patients with sarcomas of the
pulmonary arteries were a large filling defect with vascular distension, unilaterality and a lack of improvement
despite effective anticoagulation. In patients with aortic sarcomas we most frequently observed a pedunculated
appearance and an atypical location of the filling defect. The F-18 FDG PET(/CT) examinations demonstrated an
unequivocal hypermetabolism of the lesion in all cases (4/4). MRI proved lesion vascularization in 5/6 cases.
Conclusion: Intravascular unilateral or atypically located filling defects of the great vessels with vascular distension,
a pedunculated shape and lack of improvement despite effective anticoagulation are suspicious for primary
sarcoma on MDCT or MRI. MR perfusion techniques can add information on the nature of the lesion but the
findings may be subtle and equivocal. F-18 FDG PET/CT may have a potential role in these patients and may be
considered as part of the imaging workup.Background
Primary malignant sarcomas of the great vessels are ex-
ceedingly rare, representing less than 1% of all sarco-
mas [1,2]. Hence, information on these malignancies is
restricted to case reports and small retrospective series.
The most frequent sites of origin are the pulmonary
arteries and the aorta, followed by venous sarcomas,
predominantly of the inferior vena cava [1]. Pulmonary
artery sarcomas commonly arise from the pulmonary
trunk and the central left or right pulmonary artery.
The most dominant histologic subtypes of sarcomas of* Correspondence: falck.christian.von@mh-hannover.de
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reproduction in any medium, provided the orthe great vessels as reported in the literature are undif-
ferentiated intimal sarcoma and leiomyosarcoma. The
subtyping of sarcomas has changed in the last decades pri-
marily by the evolvement of modern immunohistological
techniques thus making comparisons between published
historical and contemporary studies difficult. In both,
pulmonary and aortic location, an intraluminal growth
pattern is differentiated from a less frequent mural
growth type [1-3].
The prognosis of patients with primary malignant
sarcomas of the great vessels is poor, mainly due to the
late presentation of these patients with locally advanced
disease or distant metastases. Clinical features may re-
semble those of pulmonary or aortic thromboembolic
disease [1-3]. The diagnosis may be further delayed by a
misinterpretation of imaging studies of this rare disease,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ary embolism [3-5].
The aim of this study was to retrospectively identify
typical imaging features suggestive of primary malignancy
of intrathoracic vessels in combined F-18-fluorodesoxy-
glucose positron emission tomography/computed tomog-
raphy (F-18 FDG PET/CT), multidetector computed
tomography (MDCT) and magnetic resonance imaging
(MRI). We therefore analyzed the imaging appearance of
primary sarcomas of the great vessels in F-18 FDG PET/
CT, MDCT and MRI as seen in 13 consecutive patients
who were treated in a single tertiary care university center.
Methods
Study population
This retrospective study was conducted in accordance
with the guidelines of the Declaration of Helsinki and
according to standards of the local ethics committees.
The ethical committee of Hannover Medical School
waived the need for written informed consent because
routine diagnostic data was analyzed anonymously.
Between 2002 and 2011 a total of 13 patients (m = 7,
f = 6) with histologically proven primary sarcoma of the
great vessels were treated in a single tertiary care uni-
versity hospital. The mean patient age was 57.5 (±12.2)
years, ranging from 46 to 81 years. All available imaging
studies of these patients including F-18 FDG PET/CT
(n = 3), F-18 FDG PET (n = 1), MDCT (n = 12) and
MRI (n = 6) were evaluated by two experienced readers
in consensus and typical imaging features of this rare
tumor entity were identified.
Imaging studies
The PET/CT scans were acquired 90 minutes after the
intravenous application of 5 MBq/Kg body weight of F-
18-2-fluoro-2-desoxyglucose (F-18 FDG) on a dedicated
dual-slice hybrid imaging system (Siemens biograph 2,
Forchheim, Germany) in three patients and on a PET-
only scanner in one case (Siemens ECAT Exact, Knox-
ville, TN, USA). The acquisition time was five minutes
per bed position. A total of 7 – 8 bed positions were
scanned to cover a region from the vertex to the upper
thigh. A co-registered low-dose CT was used for at-
tenuation correction and anatomical localization (tube
voltage = 130 kVp, tube current = 20mAseff (modulated),
slice collimation = 2 x 5 mm, pitch = 1.5, reconstruction
increment = 2.5 mm, reconstruction kernel = B30s). Neither
oral nor intravenous contrast agents were administered
for the combined PET/CT scan.
All CT scans were acquired on MDCT scanners with 4 –
64 simultaneously acquired sections (Siemens Somatom
Volume Zoom/Sensation 16/Emotion 16/Sensation 64,
Forchheim, Germany; General Electric VCT, Chalfont
St. Giles, UK; Toshiba Aquillion, Otawara, Japan). Thesection thickness was in the range from 0.625 mm to
5 mm and the reconstruction increment in the range
from 0.5 mm to 4 mm. The tube voltage was 120 kVp
for all examinations. Dose modulation was used with
all scanners. The MDCT scans were performed after the
power injection of 80-100 ml of an anionic iodinated con-
trast agent at a flow of 3-4 ml/s followed by a saline
chaser. The scan timing was adjusted to maximize the
contrast in the region of interest, i.e. the pulmonary arter-
ies or the thoracic and abdominal aorta. The images were
reconstructed with standard abdomen kernels, sup-
plemented by an additional high-resolution reconstruc-
tion kernel for chest scans. Multiplanar reformations
(MPR) in the coronal and sagittal orientation were
available in all cases.
The MRI scans were acquired on scanners from three
different manufacturers with a field strength of 1.5 T
(Siemens Avanto, Erlangen, Germany; Philips Intera,
Best, The Netherlands; General Electric CV/i, Chalfont
St. Giles, UK). All examinations included T1- and T2-
weighted sequences before and T1-weighted sequences
with spectral fat suppression after the injection of a
gadolinium-based contrast agent as well as a dynamic
contrast-enhanced ultra-fast gradient echo acquisition or
an MR-angiography (MRA) sequence. Three examinations
were supplemented with an additional inversion-recovery
(IR) sequence for the detection of late enhancement (LE)
and three scans included ECG-gated cine-sequences
(FIESTA/Cine Trufi).Histopathologic diagnosis
The surgically derived specimens were embedded into
paraffin and sectioned according to standard histopatho-
logic procedures. Routine staining included hematoxylin
and eosin (H&E), Elastica van Gieson (EvG) and periodic
acid-schiff (PAS). The diagnosis was supplement by add-
itional immunohistochemical stains. The tumors were
classified according to the current WHO classification of
soft tissue tumors [6].Results
Patient demographics and histopathologic diagnosis
A total of 13 patients were included in this retrospective
study (m = 7, f = 6). The mean age was 57 (±12) years.
With respect to primary pre-operative imaging studies
MDCT scans were available in 12, MR scans in 6, F-18
FDG PET/CT scans in 3 cases and an F-18 FDG PET
scan in one case. The primary tumors were located at
the right (n = 5), left (n = 1) or central (n = 3) pulmonary
artery (n = 9 in total), the right inferior pulmonary vein
(n = 1), the aortic arch (n = 1), the descending aorta (n = 1)
and the abdominal aorta (n = 1). Tumor histology was
undifferentiated intimal sarcoma (n = 8), angiosarcoma
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(n = 1). This information is summarized in Table 1.
We observed a median interval between the first im-
aging study and the final diagnosis of 11 weeks, ranging
from 0 to 12 weeks. However, the interval between the
first contact to a physician due to clinical symptoms that
could retrospectively attributed to the final diagnosis
was much longer in three cases with 30 weeks (dyspnea),
52 weeks (congestive heart failure) and 30 weeks (dys-
pnea), respectively. The primary tentative diagnoses were
pulmonary embolic disease (n = 8) and idiopathic pul-
monary hypertension (n = 1) in the patients with a tumor
in the pulmonary arteries. In cases with the tumor being
located in the aorta, the tentative diagnoses were ather-
omatous disease and chronic dissection in two cases.
The patient with the sarcoma of the right inferior pul-
monary vein was primarily treated for pneumonia as
the venous infarction as seen on a chest x-ray was
interpreted as a consolidation. One patient underwent
an MDCT scan because of B-symptoms including fever,
malaise and unintended weight-loss. The MDCT-findings
were suggestive of a contained rupture of an inflamed
aorto-bi-iliac prosthesis and the patient underwent im-
mediate surgical treatment.Table 1 Patient demographics and diagnosis
Patient # Age Sex Location Histology Primary
diagnosis








3 68 M Descending aorta UIS Atheromatous
Disease/Chronic
Dissection
4 81 M Abdominal aorta AS Contained Aortic
Rupture




6 46 M Pulmonary vein LMS Pneumonia
7 71 M Distal aortic arch AS Congestive Heart
Failure/Thrombus
























All available F-18 FDG PET(/CT), MDCT-, MRI- and
studies were reviewed with respect to the presence of
imaging features suggestive of primary malignancy of
the vascular filling defects. In patients with a sarcoma
of the pulmonary artery (n = 8), we observed the following
suspicious imaging features in varying frequency: a fill-
ing defect of the entire vessel diameter with vascular
distension (n = 8/8), a large unilateral ‘thrombus’ (n = 7/8),
lack of clinical improvement despite adequate antico-
agulation without evidence of deep venous thrombosis
(n = 4/8), an expansion beyond the vessel wall (n = 2/8, in
the follow-up examination), a heterogeneous enhancement
after the intravenous administration of a contrast agent
in MRI (n = 3/4, MRI was available in 4 patients), metabolic
activity as demonstrated by F-18 FDG PET(/CT) (n = 3/3,
PET was available in 3 patients), a pedunculated appear-
ance (n = 1/8), and local or distant metastases (n = 2/8).
The semiquantitative analysis of the metabolic activity
of the tumors in F-18 FDG PET/CT revealed SUVmax-
values of 16.1, 8.8 and 14.5, respectively. There was no
additional information gathered from the late enhance-
ment sequences. In the patients with sarcomas of the
aorta (n = 3) we observed comparable imaging features,
however, in a different frequency: a pedunculated appear-
ance (n = 2/3), an atypical location for a thrombus (n = 2),
an expansion beyond the vessel wall (n = 1/3), contrast
enhancement in MRI (n = 2/2, MRI was available in 2
patients) or MDCT (n = 1/1, MDCT was available in 1
patient) and metabolic activity as demonstrated by F-18
FDG PET/CT (n = 1/1; SUVmax = 3.6 – 5.5, PET was avail-
able in 1 patient). In the patient with pulmonary vein
sarcoma we observed a large filling defect with vascular
distension, comparable to the findings as seen in pul-
monary artery sarcoma. The related lung parenchyma
shows excessive consolidation, consistent with venous
infarction.
As deducible from the relative frequency of the above-
mentioned findings, we found a combination of indicative
imaging features in most patients. In the CTA examina-
tions of the pulmonary arteries in three patients, we
observed large, unilateral right-sided filling defects in
the pulmonary arteries that obturate the whole cross-
sectional area of the vessel and lead to a vascular ex-
pansion (Figure 1). However, pulmonary embolism was
the primary tentative diagnosis in all three cases and
the patients received accordant conservative treatment.
The follow-up examinations showed a progression of the
findings (Figure 1) or at least a lack of improvement,
respectively, despite a sufficient anticoagulation therapy
and hence strongly suggest a neoplastic nature of the
filling defects.
The demonstration of lesion vascularization using first
pass perfusion or dynamic contrast-enhanced MRI tech-
Figure 1 CT pulmonary angiography (CTPA) of a 49-year-old female patient with a myxofibrosarcoma of the right pulmonary artery.
Suspicious imaging features were already present in the primary imaging (A, C). However, the patient was treated conservatively for suspected
pulmonary embolism. A follow-up exam was acquired three month later and demonstrated massive disease progression with tumor expansion
beyond the vessel wall and local lymph node metastases (B, D)
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and inhomogeneous contrast enhancements in our pa-
tient cohort. Color-coding of the perfusion images may
facilitate the perception of the subtle signal changes
(Figure 2).
The evidence of hypermetabolism of the filling defect
as shown by F-18 FDG PET/CT, however, could be read-
ily and unequivocally appreciated in all our patients with
metabolic imaging (Figures 2, 3) and strengthened the
suspicion of malignant disease. Due to the decisive im-
plications of a radical surgical approach, a combination
of different imaging studies was requested in many
patients of our cohort. The complementary information
of morphological, functional and metabolic imaging in-
creases the diagnostic confidence and may facilitate the
therapeutic decisions as shown in Figure 3. In equivocal
cases, a whole-body staging such as PET/CT may further
increase the probability of a malignant disease by revealing
distant metastases (Figure 3).
Although few in number, our cases with sarcomas lo-
cated in the aorta suggest that the typical imaging features
are comparable to those seen in tumors occurring in
the pulmonary vasculature. Potentially suspicious imaging
findings of intraaortal filling defects include an atypicallocation for a thrombus, a pedunculated appearance and
a subtle enhancement during first-pass perfusion (Figure 4)
and hypermetabolism in F-18 FDG PET/CT (Figure 5),
consistent with the intraluminal type of aortic sarcoma.
Mural-type sarcomas show different imaging characteris-
tics with predominant extraluminal perivascular growth
and can be mistaken for inflammatory disease (Figure 6).
The findings are summarized in Table 2.
Discussion
As primary malignancies of the great vessels are excep-
tionally rare, most nuclear medicine specialists and radi-
ologists have no personal experience in diagnosing the
disease. This study therefore aimed at identifying typical
imaging features of primary sarcomas of the great vessels
using MDCT and MRI based on our single-center ex-
perience. Furthermore, we report on advanced imaging
techniques such as MR perfusion and metabolic F-18
FDG PET/CT imaging that have proven potential as tools
for possible diagnosis verification and tumor staging.
To date, about 150 cases of primary aortic sarcomas
and approximately 250 cases of primary sarcomas of the
pulmonary arteries have been reported in the English-
language world literature [1-3]. Many of these reports
Figure 2 This figure illustrates an in-depth preoperative work-up in a 46-year-old female patient with an undifferentiated intimal
sarcoma of the central pulmonary artery. Both, the MDCT (A, B) and the MRI (C, D) clearly demonstrate a subtotal occlusion of the pulmonary
trunk due to an intraluminal process. Imaging findings are suggestive of a focal expansion beyond the vessel wall (A-D, arrowheads). The MR first-pass
perfusion sequence (F) demonstrates a subtle perfusion of the lesion as compared to the non-enhanced control scan (E, circle). The F-18 FDG PET/CT
proves a high metabolic activity (SUVmax = 7.8) within the lesion (G, H) and strengthens the suspicion of malignant disease.
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the rareness of these tumors it is important for the radi-
ologist to bear this seldom differential diagnosis in mind,
especially when alerted by typical imaging findings that
raise the suspicion of a neoplastic origin of an intravascu-
lar filling defect as presented in this manuscript.Figure 3 This figure illustrates the imaging findings in a 74-year-old m
of the left pulmonary artery (A-C, F, G). Both, the MDCT and the F-18 FD
pulmonary vasculature of the right lung (A, D, E; arrowheads) as well as aThe overall prognosis of patients with sarcomas of
the great vessels is poor. Many patients have a locally
advanced state or distant metastases at the time of presen-
tation [1-3]. Hence, a timely diagnosis is essential to iden-
tify the patients in a stage of disease where an aggressive
surgical therapeutic approach with curative intent isale patient with an extensive undifferentiated intimal sarcoma
G PET/CT readily demonstrate the local embolic spread in the
distant metastasis to the brain (H, I).
Figure 4 This figure shows an example of an aortic angiosarcoma of the distal aortic arch in a 71-year-old male patient who was
treated for congestive heart failure. The MDCT and MRI images (A-D) nicely illustrate the typical pedunculated appearance of the lesion in a
location that is atypical for atheromatous thrombi. The first pass perfusion sequence (F) suggests vascularisation of the lesion as compared to the
unenhanced control acquisition (E, circle).
Figure 5 MDCT and PET/CT of a 71-year-old male patient with an undifferentiated intimal sarcoma of the descending aorta and
extension into the superior mesenteric artery (A, C). The PET/CT adds valuable information about the metabolic status of vascular filling
defect and strengthens the suspicion of malignant disease (B, D).
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Figure 6 MDCT images in axial (A) and coronal (B) orientation of a 81-year-old patient with an angiosarcoma of the abdominal aorta
who had previously undergone open aortic surgery. The extensive extramural tumor formation is clearly visualized and may be confounded
with chronic inflammatory disease and contained rupture.
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of 11 weeks between the first imaging study and the
final diagnosis. The awareness of typical imaging find-
ings presented herein may add to a shortening of this
undesirable diagnostic delay. However, the large inter-
val between the first consultation of a physician and
the final diagnosis in three of our cases is assumably of
higher prognostic relevance, but can hardly be reduced
due to the unspecific symptoms that mimic more com-
mon diseases such as pulmonary hypertension or con-
gestive heart failure [1,5,7,8].
With regard to primary malignancies of the pulmonary
arteries we observed a large filling defect with vascular
distension, unilaterality of the filling defect and a lackTable 2 Imaging features of primary sarcoma of the
great vessels
Basic imaging features
Pulmonary artery sarcoma Aortic sarcoma
Large unilateral obstruction of








Expansion beyond the vessel wall
Lack of improvement of a ‘pulmonary
embolism’ despite adequate anticoagulation
No evidence of a deep-venous thrombosis
Imaging findings during detailed work-up
High metabolic activity as demonstrated by
F-18 FDG PET or PET/CT
Lesion vascularization (as demonstrated by
contrast-enhanced dynamic or perfusion MRI or CT)
Distant metastasesof improvement despite effective anticoagulation as the
major imaging findings suggestive of malignant disease.
These findings are usually the first ‘red flags’ that can
possibly be encountered in an MDCT scan of the chest
usually acquired for unspecific clinical symptoms such
as dyspnea or chest pain. Our results are well in con-
cordance with earlier observations in the literature. Yi
et al. reported comparable findings in a group of seven
patients in a study on the MDCT-appearance of pul-
monary artery sarcomas [7]. However, they observed
extraluminal expansion in 5 of 7 patients (71%) as com-
pared to 25% (2/8) in our cohort. This difference may
be due to an advanced tumor stage in Yi’s patient group
as the findings occurred in our two patients in the
follow-up examinations showing progressive disease.
Furthermore, Yi et al. may have had more patients with
the mural form of the disease in his patient group as
opposed to the exclusively luminal form in our patients.
Fasse et al. have also seen comparable findings in five
patients [8]. We did not observe a bilateral involvement
of the central pulmonary arteries, however, it may occur
as shown in a case by Simpson and Mendelson [9].
With respect to sarcomas of the aorta we identified
an atypical location of a thrombus and a pedunculated
shape as characteristic morphologic imaging features in
two patients of our cohort, consistent with the intimal
form of aortic sarcoma as described in the literature.
Comparable findings have been reported by Bendel et al.
[3]. Our single case of a patient with the mural disease
pattern who had previously undergone aortic surgery is
well in concordance with a few reports in the literature
that describe the development of aortic sarcoma in pa-
tients after open or endovascular aortic repair. Whether
the graft itself or a chronic perigraft infection might
contribute to the induction of malignancy in the aortic
wall remains subject to discussion, as the number of
cases is very limited [10,11]. One patient of our cohort
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which is even less frequently reported in the literature
than pulmonary artery sarcoma [12].
When an atypical vascular filling defect is noticed base
on the criteria described above, further imaging workup
is usually recommended to verify the suspicion of ma-
lignant disease. Different imaging modalities such as
dynamic MDCT and MRI examinations for the evaluation
of lesion vascularization or metabolic imaging using F-18
FDG PET(/CT) are possible examinations whose potential
benefits have been sporadically described in the literature.
There is only sparse data on the role of F-18 FDG PET
(/CT) for the imaging of primary sarcomas of the great
vessels, mainly in patients with pulmonary artery involve-
ment. However, the few cases reported in the literature
are promising [13-16]. Ito et al. reported on three patients
with pulmonary artery sarcomas and demonstrated that
the mean SUVmax of 7.6 was significantly higher than in
patients with pulmonary embolism [13]. Wittram and
Scott observed SUVmax values in the range from 0.45 to
3.03 for acute pulmonary emboli, which is considerably
lower than the SUVmax values reported for pulmonary
sarcomas [17]. Another small series of three patients was
published by Tueller et al. with an SUVmax of 5.2 (reported
only for one patient) [16]. Treglia et al. recently reported
an SUVmax of 13 for a primary pulmonary epitheloid
angiosarcoma that presented as an intrapulmonary mass
[18]. There is even less experience in patients with aortic
sarcoma [19,20] or sarcoma of the pulmonary veins [21].
Our own results on three patients are also encouraging.
We observed unequivocal positive findings in all four
patients that underwent a F-18 FDG PET or F-18 FDG
PET(/CT) examination. Our mean SUVmax of 13.1 for
patients with pulmonary artery disease was even higher
than the values reported in the literature. As PET/CT
usually is a whole-body examination it does not only
help to decide on the possibly malignant nature of a
filling defect, but at the same time serves as a whole-
body staging modality. In one of our cases, F-18 FDG
PET(/CT) was able to demonstrate embolic metastases
in the lungs as well as a peripheral metastasis to the
brain (Figure 5).
Although described in most reports of primary sarco-
mas of the great vessels, there is only few quantitative
data on the degree of enhancement or perfusion of these
tumors. Kacl et al. reported on dynamic MRI in four
patients with sarcomas of the pulmonary arteries and
found a ‘considerable variability’ of the contrast enhance-
ment, which was interpreted as being dependent on the
degree of differentiation [22]. Howarth et al. described
a single case in which an MRI first-pass perfusion
sequence was used to prove the vascularization of the
lesion [23]. Fasse et al. reported on MDCT and MRI
findings in five patients with sarcomas of the pulmonaryarteries and found only MR imaging suitable for the
evaluation of lesion enhancement [8]. However, tumor
vascularization cannot be demonstrated in all cases [8].
In our patient population, MR demonstrated a contrast
enhancement of the lesions in 3 out of 4 MRI scans of
patients with pulmonary disease and in both MRI scans
available in the patients with aortic tumors. Notably, the
enhancement was subtle in all our patients and required
a thorough analysis of the contrast-enhanced sequences.
No enhancement was visualized on standard MDCT
examinations, except for the patient with the extensive
mural aortic sarcoma. However, we did not evaluate the
possible value of dedicated MDCT perfusion techniques.
Besides the evaluation of possible lesion perfusion, MRI
has an additional value in the depiction of the relationship
between the tumor and its surrounding structures and
may assist the preoperative planning, especially when
ECG-gated cine sequences are used.
A number of important limitations of our manuscript
need to be addressed. First of all and most obvious, the
number of patients in our study is limited and the im-
aging studies available for our analyses were heteroge-
neous and do not follow a specific protocol. However, as
already outlined above, sarcomas of the great vessels are
exceedingly rare and most reports in the literature are
therefore limited to descriptions of single cases or small
series. To the best of our knowledge, our manuscript
represents the largest study group that has been evaluated
with respect to the imaging findings. Second, we did
not compare our imaging findings to a contrast group
such as patients with pulmonary embolic disease or severe
aortic atheromatosis. However, the selection of such
control groups would be highly artificial. Furthermore,
the number of patients in our study is too limited to calcu-
late statistical significances or sensitivities and specificities.
In addition, we did not evaluate the potential role of trans-
thoracic or transesophageal echocardiography in our
patient cohort. Depending on the location, these mo-
dalities may also serve as a viable tool for the depiction
of the tumor. However, as the field of view and the
capability to characterize soft tissues are limited, echo-
cardiography has its strongest potential in patients with
cardiac sarcomas and is inferior to MDCT and MRI in
cases of extracardiac disease [3].
Conclusion
In conclusion, if an intraluminal filling defect of a great
vessel that is incidentally detected on a routine MDCT
or MRI scan shows the characteristic imaging findings
outlined in this manuscript, primary sarcoma should be
taken into consideration and further diagnostic workup
is recommended to avoid any delay in the diagnosis of
this rare disease. MR perfusion techniques may add in-
formation on the nature of the lesion but the findings
von Falck et al. BMC Medical Imaging 2013, 13:25 Page 9 of 9
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perience, we see a potential role of F-18 FDG PET/CT
in these patients and suggest it to be considered as part
of the imaging workup in these patients.
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